Our work stands on multi-decade research from academic and industry groups united by a goal of eradicating cancer. We honor their discoveries as we unlock new ways to treat the world's deadliest tumors.
Our work is based on a multi-decade research from academic and industry groups. All of our insights are built on the tremendous dedication and unwavering commitment of individuals around the world working with one goal in mind – eradicate cancer once and for all.
Herein our aim is to acknowledge some of the works that inspire and guide us as we continue on our quest to unlock new ways to treat some of the deadliest cancers.
Our Work
Our findings highlight a significant functional relationship between CTR1 and NDUFS7, providing a foundation for the development of new cancer therapies.
Our Work
In the publication we present our work on a first-in-class small-molecule NDUFS7 antagonist that inhibits oxidative phosphorylation (OXPHOS) for the treatment of pancreatic cancer.
Metabolic rewiring
Demonstrated how PDAC tumors increase Complex I flux under treatment pressure, informing our biomarker strategy.
Resistance profiling
Sequencing work that highlighted mitochondrial dependencies in chemotherapy-escaped clones.
Combination science
Inspired our ongoing work pairing AGB374 with ROCK1/2 inhibitors to collapse tumor energetics.
Precision medicine
Provided the blueprint for our patient-selection panels rooted in metabolic state.
our work
Herein, we reported the discovery, optimization, and structure−activity relationship (SAR) study of a series of novel OXPHOS inhibitors.
our work
Herein, we described our lead optimization campaign on a series of benzene-1,4-disulfonamides as novel OXPHOS complex I inhibitors.